Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 33 entries
Sorted by: Best Match Show Resources per page
Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours.

Journal of Cancer

Mairinger FD, Walter RF, Theegarten D, Hager T, Vollbrecht C, Christoph DC, Worm K, Ting S, Werner R, Stamatis G, Mairinger T, Baba H, Zarogoulidis K, Huang H, Li Q, Tsakiridis K, Zarogoulidis P, Schmid KW, Wohlschlaeger J.
PMID: 25157275
J Cancer. 2014 Aug 01;5(8):646-54. doi: 10.7150/jca.9955. eCollection 2014.

BACKGROUND: Proteasomal subunit PSMB4 was suggested to be a survival gene in an animal model of hepatocellular carcinoma and in glioblastoma cell lines. In pulmonary adenocarcinoma, a high expression of these genes was found to be associated with poor...

Cite
Mairinger FD, Walter RF, Theegarten D, et al. Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours. J Cancer. 2014;5(8):646-54doi: 10.7150/jca.9955.
Mairinger, F. D., Walter, R. F., Theegarten, D., Hager, T., Vollbrecht, C., Christoph, D. C., Worm, K., Ting, S., Werner, R., Stamatis, G., Mairinger, T., Baba, H., Zarogoulidis, K., Huang, H., Li, Q., Tsakiridis, K., Zarogoulidis, P., Schmid, K. W., & Wohlschlaeger, J. (2014). Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours. Journal of Cancer, 5(8), 646-54. https://doi.org/10.7150/jca.9955
Mairinger, Fabian Dominik, et al. "Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours." Journal of Cancer vol. 5,8 (2014): 646-54. doi: https://doi.org/10.7150/jca.9955
Mairinger FD, Walter RF, Theegarten D, Hager T, Vollbrecht C, Christoph DC, Worm K, Ting S, Werner R, Stamatis G, Mairinger T, Baba H, Zarogoulidis K, Huang H, Li Q, Tsakiridis K, Zarogoulidis P, Schmid KW, Wohlschlaeger J. Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours. J Cancer. 2014 Aug 01;5(8):646-54. doi: 10.7150/jca.9955. eCollection 2014. PMID: 25157275; PMCID: PMC4142326.
Copy Download .nbib Format: NLM
Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations.

The Journal of pathology

Jurmeister P, Wrede N, Hoffmann I, Vollbrecht C, Heim D, Hummel M, Wolkenstein P, Koch I, Heynol V, Schmitt WD, Thieme A, Teichmann D, Sers C, von Deimling A, Thierauf JC, von Laffert M, Klauschen F, Capper D.
PMID: 34564861
J Pathol. 2022 Jan;256(1):61-70. doi: 10.1002/path.5808. Epub 2021 Oct 25.

Cutaneous, ocular, and mucosal melanomas are histologically indistinguishable tumors that are driven by a different spectrum of genetic alterations. With current methods, identification of the site of origin of a melanoma metastasis is challenging. DNA methylation profiling has shown...

Cite
Jurmeister P, Wrede N, Hoffmann I, et al. Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. J Pathol. 2021;256(1):61-70doi: 10.1002/path.5808.
Jurmeister, P., Wrede, N., Hoffmann, I., Vollbrecht, C., Heim, D., Hummel, M., Wolkenstein, P., Koch, I., Heynol, V., Schmitt, W. D., Thieme, A., Teichmann, D., Sers, C., von Deimling, A., Thierauf, J. C., von Laffert, M., Klauschen, F., & Capper, D. (2022). Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. The Journal of pathology, 256(1), 61-70. https://doi.org/10.1002/path.5808
Jurmeister, Philipp, et al. "Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations." The Journal of pathology vol. 256,1 (2022): 61-70. doi: https://doi.org/10.1002/path.5808
Jurmeister P, Wrede N, Hoffmann I, Vollbrecht C, Heim D, Hummel M, Wolkenstein P, Koch I, Heynol V, Schmitt WD, Thieme A, Teichmann D, Sers C, von Deimling A, Thierauf JC, von Laffert M, Klauschen F, Capper D. Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. J Pathol. 2022 Jan;256(1):61-70. doi: 10.1002/path.5808. Epub 2021 Oct 25. PMID: 34564861.
Copy Download .nbib Format: NLM
Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids.

Clinical lung cancer

Frost N, Kollmeier J, Misch D, Vollbrecht C, Grah C, Matthes B, Pultermann D, Olive E, Raspe M, Ochsenreither S, von Laffert M, Suttorp N, Witzenrath M, Grohé C.
PMID: 33648877
Clin Lung Cancer. 2021 Sep;22(5):411-422. doi: 10.1016/j.cllc.2021.02.001. Epub 2021 Feb 06.

INTRODUCTION: Pembrolizumab is a highly effective standard of care in PD-L1 overexpressing (≥ 50%) non-small-cell lung cancer. However, a substantial share of patients from everyday clinical practice is treated without clear evidence from clinical trials.PATIENTS AND METHODS: We performed...

Cite
Frost N, Kollmeier J, Misch D, et al. Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids. Clin Lung Cancer. 2021;22(5):411-422doi: 10.1016/j.cllc.2021.02.001.
Frost, N., Kollmeier, J., Misch, D., Vollbrecht, C., Grah, C., Matthes, B., Pultermann, D., Olive, E., Raspe, M., Ochsenreither, S., von Laffert, M., Suttorp, N., Witzenrath, M., & Grohé, C. (2021). Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids. Clinical lung cancer, 22(5), 411-422. https://doi.org/10.1016/j.cllc.2021.02.001
Frost, Nikolaj, et al. "Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids." Clinical lung cancer vol. 22,5 (2021): 411-422. doi: https://doi.org/10.1016/j.cllc.2021.02.001
Frost N, Kollmeier J, Misch D, Vollbrecht C, Grah C, Matthes B, Pultermann D, Olive E, Raspe M, Ochsenreither S, von Laffert M, Suttorp N, Witzenrath M, Grohé C. Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids. Clin Lung Cancer. 2021 Sep;22(5):411-422. doi: 10.1016/j.cllc.2021.02.001. Epub 2021 Feb 06. PMID: 33648877.
Copy Download .nbib Format: NLM
Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium.

The Journal of molecular diagnostics : JMD

Fenizia F, Alborelli I, Costa JL, Vollbrecht C, Bellosillo B, Dinjens W, Endris V, Heydt C, Leonards K, Merkelback-Bruse S, Pfarr N, van Marion R, Allen C, Chaudhary R, Gottimukkala R, Hyland F, Wong-Ho E, Jermann P, Machado JC, Hummel M, Stenzinger A, Normanno N.
PMID: 33964449
J Mol Diagn. 2021 Jul;23(7):882-893. doi: 10.1016/j.jmoldx.2021.04.008. Epub 2021 May 06.

Tumor mutation burden (TMB) is evaluated as a biomarker of response to immunotherapy. We present the efforts of the Onconetwork Immuno-Oncology Consortium to validate a commercial targeted sequencing test for TMB calculation. A three-phase study was designed to validate...

Cite
Fenizia F, Alborelli I, Costa JL, et al. Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium. J Mol Diagn. 2021;23(7):882-893doi: 10.1016/j.jmoldx.2021.04.008.
Fenizia, F., Alborelli, I., Costa, J. L., Vollbrecht, C., Bellosillo, B., Dinjens, W., Endris, V., Heydt, C., Leonards, K., Merkelback-Bruse, S., Pfarr, N., van Marion, R., Allen, C., Chaudhary, R., Gottimukkala, R., Hyland, F., Wong-Ho, E., Jermann, P., Machado, J. C., Hummel, M., Stenzinger, A., & Normanno, N. (2021). Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium. The Journal of molecular diagnostics : JMD, 23(7), 882-893. https://doi.org/10.1016/j.jmoldx.2021.04.008
Fenizia, Francesca, et al. "Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium." The Journal of molecular diagnostics : JMD vol. 23,7 (2021): 882-893. doi: https://doi.org/10.1016/j.jmoldx.2021.04.008
Fenizia F, Alborelli I, Costa JL, Vollbrecht C, Bellosillo B, Dinjens W, Endris V, Heydt C, Leonards K, Merkelback-Bruse S, Pfarr N, van Marion R, Allen C, Chaudhary R, Gottimukkala R, Hyland F, Wong-Ho E, Jermann P, Machado JC, Hummel M, Stenzinger A, Normanno N. Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium. J Mol Diagn. 2021 Jul;23(7):882-893. doi: 10.1016/j.jmoldx.2021.04.008. Epub 2021 May 06. PMID: 33964449.
Copy Download .nbib Format: NLM
Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis.

Pathology, research and practice

Wrede N, Hoffmann I, Vollbrecht C, Koch I, Wolkenstein P, Klauschen F, Capper D, von Laffert M, Jurmeister P.
PMID: 34844086
Pathol Res Pract. 2021 Nov 22;229:153689. doi: 10.1016/j.prp.2021.153689. Epub 2021 Nov 22.

Mucosal melanomas arise from the mucosal lining of various organs. Their etiology is currently unknown and there are no tissue-based methods to differentiate it from cutaneous melanomas. Furthermore, prognostic and predictive markers (e.g. for immune checkpoint inhibition) are lacking....

Cite
Wrede N, Hoffmann I, Vollbrecht C, et al. Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis. Pathol Res Pract. 2021;229:153689doi: 10.1016/j.prp.2021.153689.
Wrede, N., Hoffmann, I., Vollbrecht, C., Koch, I., Wolkenstein, P., Klauschen, F., Capper, D., von Laffert, M., & Jurmeister, P. (2021). Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis. Pathology, research and practice, 229153689. https://doi.org/10.1016/j.prp.2021.153689
Wrede, Niklas, et al. "Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis." Pathology, research and practice vol. 229 (2021): 153689. doi: https://doi.org/10.1016/j.prp.2021.153689
Wrede N, Hoffmann I, Vollbrecht C, Koch I, Wolkenstein P, Klauschen F, Capper D, von Laffert M, Jurmeister P. Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis. Pathol Res Pract. 2021 Nov 22;229:153689. doi: 10.1016/j.prp.2021.153689. Epub 2021 Nov 22. PMID: 34844086.
Copy Download .nbib Format: NLM
The prefusion structure of herpes simplex virus glycoprotein B.

Science advances

Vollmer B, Pražák V, Vasishtan D, Jefferys EE, Hernandez-Duran A, Vallbracht M, Klupp BG, Mettenleiter TC, Backovic M, Rey FA, Topf M, Grünewald K.
PMID: 32978151
Sci Adv. 2020 Sep 25;6(39). doi: 10.1126/sciadv.abc1726. Print 2020 Sep.

Cell entry of enveloped viruses requires specialized viral proteins that mediate fusion with the host membrane by substantial structural rearrangements from a metastable pre- to a stable postfusion conformation. This metastability renders the herpes simplex virus 1 (HSV-1) fusion...

Cite
Vollmer B, Pražák V, Vasishtan D, et al. The prefusion structure of herpes simplex virus glycoprotein B. Sci Adv. 2020;6(39)doi: 10.1126/sciadv.abc1726.
Vollmer, B., Pražák, V., Vasishtan, D., Jefferys, E. E., Hernandez-Duran, A., Vallbracht, M., Klupp, B. G., Mettenleiter, T. C., Backovic, M., Rey, F. A., Topf, M., & Grünewald, K. (2020). The prefusion structure of herpes simplex virus glycoprotein B. Science advances, 6(39), . https://doi.org/10.1126/sciadv.abc1726
Vollmer, B, et al. "The prefusion structure of herpes simplex virus glycoprotein B." Science advances vol. 6,39 (2020). doi: https://doi.org/10.1126/sciadv.abc1726
Vollmer B, Pražák V, Vasishtan D, Jefferys EE, Hernandez-Duran A, Vallbracht M, Klupp BG, Mettenleiter TC, Backovic M, Rey FA, Topf M, Grünewald K. The prefusion structure of herpes simplex virus glycoprotein B. Sci Adv. 2020 Sep 25;6(39). doi: 10.1126/sciadv.abc1726. Print 2020 Sep. PMID: 32978151; PMCID: PMC7518877.
Copy Download .nbib Format: NLM
Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations.

The Journal of pathology

Jurmeister P, Wrede N, Hoffmann I, Vollbrecht C, Heim D, Hummel M, Wolkenstein P, Koch I, Heynol V, Schmitt WD, Thieme A, Teichmann D, Sers C, von Deimling A, Thierauf JC, von Laffert M, Klauschen F, Capper D.
PMID: 34564861
J Pathol. 2022 Jan;256(1):61-70. doi: 10.1002/path.5808. Epub 2021 Oct 25.

Cutaneous, ocular, and mucosal melanomas are histologically indistinguishable tumors that are driven by a different spectrum of genetic alterations. With current methods, identification of the site of origin of a melanoma metastasis is challenging. DNA methylation profiling has shown...

Cite
Jurmeister P, Wrede N, Hoffmann I, et al. Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. J Pathol. 2021;256(1):61-70doi: 10.1002/path.5808.
Jurmeister, P., Wrede, N., Hoffmann, I., Vollbrecht, C., Heim, D., Hummel, M., Wolkenstein, P., Koch, I., Heynol, V., Schmitt, W. D., Thieme, A., Teichmann, D., Sers, C., von Deimling, A., Thierauf, J. C., von Laffert, M., Klauschen, F., & Capper, D. (2022). Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. The Journal of pathology, 256(1), 61-70. https://doi.org/10.1002/path.5808
Jurmeister, Philipp, et al. "Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations." The Journal of pathology vol. 256,1 (2022): 61-70. doi: https://doi.org/10.1002/path.5808
Jurmeister P, Wrede N, Hoffmann I, Vollbrecht C, Heim D, Hummel M, Wolkenstein P, Koch I, Heynol V, Schmitt WD, Thieme A, Teichmann D, Sers C, von Deimling A, Thierauf JC, von Laffert M, Klauschen F, Capper D. Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. J Pathol. 2022 Jan;256(1):61-70. doi: 10.1002/path.5808. Epub 2021 Oct 25. PMID: 34564861.
Copy Download .nbib Format: NLM
Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al' by Benucci .

Annals of the rheumatic diseases

Schulze-Koops H, Krueger K, Vallbracht IV, Hasseli R, Skapenko A.
PMID: 32753421
Ann Rheum Dis. 2020 Aug 04; doi: 10.1136/annrheumdis-2020-218686. Epub 2020 Aug 04.

No abstract available.

Cite
Schulze-Koops H, Krueger K, Vallbracht IV, et al. Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al' by Benucci . Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218686.
Schulze-Koops, H., Krueger, K., Vallbracht, I. V., Hasseli, R., & Skapenko, A. (2020). Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al' by Benucci . Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218686
Schulze-Koops, Hendrik, et al. "Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al' by Benucci ." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218686
Schulze-Koops H, Krueger K, Vallbracht IV, Hasseli R, Skapenko A. Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al' by Benucci . Ann Rheum Dis. 2020 Aug 04; doi: 10.1136/annrheumdis-2020-218686. Epub 2020 Aug 04. PMID: 32753421.
Copy Download .nbib Format: NLM
Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis.

Journal of Cancer

Mairinger FD, Walter RF, Werner R, Christoph DC, Ting S, Vollbrecht C, Zarogoulidis K, Huang H, Li Q, Schmid KW, Wohlschlaeger J, Zarogoulidis P.
PMID: 24959299
J Cancer. 2014 May 15;5(6):465-71. doi: 10.7150/jca.9235. eCollection 2014.

BACKGROUND: Lung cancer still remains the leading cause of cancer for men after prostate cancer and breast cancer for women. Angiogenesis is considered a major microenvironment modifier.MATERIAL AND METHODS: Demographic data and study design; The study is based on...

Cite
Mairinger FD, Walter RF, Werner R, et al. Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis. J Cancer. 2014;5(6):465-71doi: 10.7150/jca.9235.
Mairinger, F. D., Walter, R. F., Werner, R., Christoph, D. C., Ting, S., Vollbrecht, C., Zarogoulidis, K., Huang, H., Li, Q., Schmid, K. W., Wohlschlaeger, J., & Zarogoulidis, P. (2014). Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis. Journal of Cancer, 5(6), 465-71. https://doi.org/10.7150/jca.9235
Mairinger, Fabian D, et al. "Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis." Journal of Cancer vol. 5,6 (2014): 465-71. doi: https://doi.org/10.7150/jca.9235
Mairinger FD, Walter RF, Werner R, Christoph DC, Ting S, Vollbrecht C, Zarogoulidis K, Huang H, Li Q, Schmid KW, Wohlschlaeger J, Zarogoulidis P. Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis. J Cancer. 2014 May 15;5(6):465-71. doi: 10.7150/jca.9235. eCollection 2014. PMID: 24959299; PMCID: PMC4066358.
Copy Download .nbib Format: NLM
Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis.

Pathology, research and practice

Wrede N, Hoffmann I, Vollbrecht C, Koch I, Wolkenstein P, Klauschen F, Capper D, von Laffert M, Jurmeister P.
PMID: 34844086
Pathol Res Pract. 2021 Nov 22;229:153689. doi: 10.1016/j.prp.2021.153689. Epub 2021 Nov 22.

Mucosal melanomas arise from the mucosal lining of various organs. Their etiology is currently unknown and there are no tissue-based methods to differentiate it from cutaneous melanomas. Furthermore, prognostic and predictive markers (e.g. for immune checkpoint inhibition) are lacking....

Cite
Wrede N, Hoffmann I, Vollbrecht C, et al. Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis. Pathol Res Pract. 2021;229:153689doi: 10.1016/j.prp.2021.153689.
Wrede, N., Hoffmann, I., Vollbrecht, C., Koch, I., Wolkenstein, P., Klauschen, F., Capper, D., von Laffert, M., & Jurmeister, P. (2021). Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis. Pathology, research and practice, 229153689. https://doi.org/10.1016/j.prp.2021.153689
Wrede, Niklas, et al. "Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis." Pathology, research and practice vol. 229 (2021): 153689. doi: https://doi.org/10.1016/j.prp.2021.153689
Wrede N, Hoffmann I, Vollbrecht C, Koch I, Wolkenstein P, Klauschen F, Capper D, von Laffert M, Jurmeister P. Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis. Pathol Res Pract. 2021 Nov 22;229:153689. doi: 10.1016/j.prp.2021.153689. Epub 2021 Nov 22. PMID: 34844086.
Copy Download .nbib Format: NLM
Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau.

Alzheimer's & dementia (New York, N. Y.)

Rosenqvist N, Asuni AA, Andersson CR, Christensen S, Daechsel JA, Egebjerg J, Falsig J, Helboe L, Jul P, Kartberg F, Pedersen LØ, Sigurdsson EM, Sotty F, Skjødt K, Stavenhagen JB, Volbracht C, Pedersen JT.
PMID: 30386817
Alzheimers Dement (N Y). 2018 Oct 14;4:521-534. doi: 10.1016/j.trci.2018.09.005. eCollection 2018.

INTRODUCTION: The abnormal hyperphosphorylation of the microtubule-associated protein tau plays a crucial role in neurodegeneration in Alzheimer's disease (AD) and other tauopathies.METHODS: Highly specific and selective anti-pS396-tau antibodies have been generated using peptide immunization with screening against pathologic hyperphosphorylated...

Cite
Rosenqvist N, Asuni AA, Andersson CR, et al. Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau. Alzheimers Dement (N Y). 2018;4:521-534doi: 10.1016/j.trci.2018.09.005.
Rosenqvist, N., Asuni, A. A., Andersson, C. R., Christensen, S., Daechsel, J. A., Egebjerg, J., Falsig, J., Helboe, L., Jul, P., Kartberg, F., Pedersen, L. �. �., Sigurdsson, E. M., Sotty, F., Skjødt, K., Stavenhagen, J. B., Volbracht, C., & Pedersen, J. T. (2018). Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau. Alzheimer's & dementia (New York, N. Y.), 4521-534. https://doi.org/10.1016/j.trci.2018.09.005
Rosenqvist, Nina, et al. "Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau." Alzheimer's & dementia (New York, N. Y.) vol. 4 (2018): 521-534. doi: https://doi.org/10.1016/j.trci.2018.09.005
Rosenqvist N, Asuni AA, Andersson CR, Christensen S, Daechsel JA, Egebjerg J, Falsig J, Helboe L, Jul P, Kartberg F, Pedersen LØ, Sigurdsson EM, Sotty F, Skjødt K, Stavenhagen JB, Volbracht C, Pedersen JT. Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau. Alzheimers Dement (N Y). 2018 Oct 14;4:521-534. doi: 10.1016/j.trci.2018.09.005. eCollection 2018. PMID: 30386817; PMCID: PMC6205114.
Copy Download .nbib Format: NLM
Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations.

The Journal of pathology

Jurmeister P, Wrede N, Hoffmann I, Vollbrecht C, Heim D, Hummel M, Wolkenstein P, Koch I, Heynol V, Schmitt WD, Thieme A, Teichmann D, Sers C, von Deimling A, Thierauf JC, von Laffert M, Klauschen F, Capper D.
PMID: 34564861
J Pathol. 2021 Sep 26; doi: 10.1002/path.5808. Epub 2021 Sep 26.

Cutaneous, ocular, and mucosal melanomas are histologically indistinguishable tumors that are driven by a different spectrum of genetic alterations. With current methods, identification of the site of origin of a melanoma metastasis is challenging. DNA methylation profiling has shown...

Cite
Jurmeister P, Wrede N, Hoffmann I, et al. Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. J Pathol. 2021;doi: 10.1002/path.5808.
Jurmeister, P., Wrede, N., Hoffmann, I., Vollbrecht, C., Heim, D., Hummel, M., Wolkenstein, P., Koch, I., Heynol, V., Schmitt, W. D., Thieme, A., Teichmann, D., Sers, C., von Deimling, A., Thierauf, J. C., von Laffert, M., Klauschen, F., & Capper, D. (2021). Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. The Journal of pathology, . https://doi.org/10.1002/path.5808
Jurmeister, Philipp, et al. "Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations." The Journal of pathology vol. (2021). doi: https://doi.org/10.1002/path.5808
Jurmeister P, Wrede N, Hoffmann I, Vollbrecht C, Heim D, Hummel M, Wolkenstein P, Koch I, Heynol V, Schmitt WD, Thieme A, Teichmann D, Sers C, von Deimling A, Thierauf JC, von Laffert M, Klauschen F, Capper D. Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. J Pathol. 2021 Sep 26; doi: 10.1002/path.5808. Epub 2021 Sep 26. PMID: 34564861.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 33 entries